🐋 NBIX $2.8M LEAP Bet: Someone Just Made a 20-Month Conviction Call on Neurocrine!

📅 April 15, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just loaded up $2.8 MILLION on NBIX December 2027 call options — buying 2,000 contracts of the $170 strike LEAP with ZERO prior open interest. This is a brand-new position, opened from scratch today, with 20 months to expiration and the stock sitting 29% below the strike. Translation: A sophisticated long-term investor just made a big conviction bet that Neurocrine's INGREZZA franchise + the new Soleno acquisition will drive a meaningful re-rating over the next two years.

---

📊 Company Overview

Neurocrine Biosciences (NBIX) is a leading neuroscience pharma company pivoting into a multi-franchise biopharma platform:

• Market Cap: $13.1B (NASDAQ)
• Industry: Pharmaceutical / Neuroscience / Rare Disease
• Current Price: $131.37
• Primary Products: INGREZZA (tardive dyskinesia, $2.5B revenue), CRENESSITY (congenital adrenal hyperplasia, $301M first-year), and soon VYKAT XR (Prader-Willi syndrome via Soleno acquisition)

Neurocrine is in the middle of a strategic transformation — from a one-drug wonder into a three-product rare-disease/neuroscience platform. The stock has pulled back from $160 highs, and apparently one big player sees that as an opportunity.

---

💰 The Option Flow Breakdown

📊 The Tape (April 15, 2026 @ 14:04:20)

🤓 What This Actually Means

This is a deep conviction long-term bullish bet. Here's what makes it exceptional:

• 💸 Premium paid: $2.8M ($14.20 per contract × 2,000 contracts × 100 shares)
• 🎯 Strike vs spot: $170 strike when stock is at $131.37 — needs a 29.4% move to get in-the-money
• ⏰ Time horizon: December 17, 2027 — that's 20 MONTHS from today. This trader is not in a hurry
• 🚨 ZERO prior open interest: This isn't adding to an existing position — this is a fresh, original bet opened right now on this specific strike/expiry combination
• 📊 Size: 2,000 contracts control 200,000 shares of NBIX, worth ~$26.3M at current prices

What's really happening here: This is a LEAP play — Long-term Equity Anticipation Position. The buyer is paying $14.20/share for the right to own NBIX at $170 any time before December 2027. They break even at $184.20 ($170 strike + $14.20 premium). For this trade to pay off, NBIX needs to rally about 40% from here.

The thesis is straightforward: by late 2027, Neurocrine will have a fully integrated three-product portfolio (INGREZZA growing toward $3B, CRENESSITY maturing, VYKAT XR ramping post-Soleno close), and the Soleno acquisition proves it can execute a major deal. Add in potential Phase 3 data from osavampator (adjunctive MDD) in 2027 and this becomes a story worth $170+.

Unusual Score: 🔥 HIGH — 2,000 contracts vs 0 open interest. This is the ENTIRE open interest in this strike/expiry — created from zero by this single trader. A few times a year you see someone open a brand-new LEAP position at this size with zero prior OI. It signals a deliberate, researched entry, not noise.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

NBIX has had a rough run from its $160 52-week highs. The stock is down roughly 18% from those highs, reflecting a combination of biotech sector pressure, Soleno acquisition digestion (the $2.9B deal drew skeptical coverage initially), and a near-term catalyst vacuum heading into 2026.

Key observations:

• 📉 Pullback from highs: $160 to $131 is a meaningful correction, and the whale sees this as a buying opportunity
• 📊 Still 35-40% below analyst consensus: Average analyst PT of $175-$183 gives context for the $170 LEAP strike — that's literally where the analyst community thinks fair value is
• 🎢 Biotech vol: The sector is inherently volatile around data readouts; the 2027 osavampator Phase 3 data will be a major binary event
• 💡 Valuation context: At 28x P/E on a company growing earnings with three profitable products, NBIX isn't expensive on a sector-adjusted basis

Gamma-Based Support & Resistance Analysis

Current Price: $131.37

The gamma map for NBIX is notably light — typical for a mid-cap biotech where options market depth is thinner than mega-caps:

🔵 Support Levels (Put Gamma Below Price):

• $130 — Nearest and strongest support, just 1.4% below current price (0.64B total GEX, nearly equal call/put gamma) — this is the near-term floor
• $125 — Secondary support at 0.11B GEX (5.2% away) — the put gamma actually slightly dominates here (bearish dealer positioning at this level)
• $120 — Moderate floor at 0.17B GEX (~8.9% away)
• $115 — Deeper support at 0.11B GEX (~12.7% away)
• $110 — Extended floor at 0.012B GEX, 16.5% below current price

🟠 Resistance Levels (Call Gamma Above Price):

• $135 — First resistance, only 2.7% overhead (0.11B total GEX) — a relatively weak ceiling
• $140 — Second resistance at 0.26B GEX (~6.5% overhead) — modest speed bump
• $145 — Third resistance at 0.36B total GEX (~10% overhead) — the first meaningful wall
• $150 — Fourth resistance at 0.037B GEX (13.8% overhead)
• $155 — Extended ceiling at 0.009B GEX (~17.6% away)

What this means for traders: The gamma structure is relatively muted for NBIX — this stock moves on fundamentals and data readouts more than dealer hedging flows. The $130 level is your immediate floor. Above, the resistance levels are all modest, meaning a fundamental catalyst (strong Q1 earnings May 5, or Soleno close confirmation) could easily propel the stock through $135-$145 without major gamma headwinds.

Net GEX Bias: Slightly Bearish (0.93B call gamma vs 1.08B put gamma) — Dealers hold slightly more put gamma than call gamma, suggesting modest downside drift pressure without a positive catalyst. This is consistent with the stock's recent underperformance.

Implied Move Analysis

Options market pricing for upcoming expirations (as of April 15, 2026):

• 📅 Weekly OPEX (April 17 — 2 days): ±$3.55 (±2.69%) → Range: $128.34 - $135.43

Translation: With April OPEX in 2 days, the market prices a 2.69% swing for NBIX — roughly $3.55 in either direction. The lower bound at $128.34 sits just above the $130 gamma support floor. The upper bound at $135.43 aligns almost exactly with the first gamma resistance level at $135.

Key insight for the LEAP buyer: They're not playing the weekly noise. With 20 months to expiration, the near-term implied move ($3.55) is almost irrelevant to their thesis. They need NBIX to add roughly $53 in value over 20 months — a task that depends on INGREZZA growth, Soleno integration, and a potential Phase 3 data win in 2027, NOT on what happens in the next 2 days.

---

🎪 Catalysts

🔥 Upcoming Catalysts (Next 6 Months)

Q1 2026 Earnings — May 5, 2026 (20 DAYS AWAY!) 📊

Neurocrine reports Q1 2026 results on May 5 with the press release at 1:00 PM PT. The market wants to see:

• INGREZZA quarterly trajectory toward the $2.7B-$2.8B 2026 guide
• CRENESSITY prescription trends — is the $301M first-year momentum accelerating?
• Soleno integration timeline update and VYKAT XR commercial outlook
• Expanded sales force deployment update (launching H2 2026)

Soleno Acquisition Close (Expected H1 2026) 🤝

Neurocrine's $2.9B acquisition of Soleno Therapeutics adds VYKAT XR — a drug generating $92M per quarter ($370M+ annualized run-rate) for Prader-Willi syndrome. When this closes, Neurocrine becomes a three-product company overnight. The deal is subject to regulatory approvals and customary closing conditions.

🚀 Longer-Term Catalysts (2027 — THE REAL PRIZE FOR THIS LEAP)

Osavampator Phase 3 Data — 2027 📊

Five Phase 3 registrational studies for osavampator as an adjunctive treatment for major depressive disorder began enrolling in January 2025. Data readouts are expected in 2027 — right in the window of this LEAP. MDD is a multi-billion-dollar indication. A positive Phase 3 result could be a massive re-rating event.

INGREZZA Sales Force Expansion — H2 2026 🏭

The expanded sales force deploys in H2 2026 to drive additional INGREZZA volume growth beyond the current ~10% annual guide. This is a planned step-up in commercial investment that analysts at H.C. Wainwright cite as a key driver for their $215 price target.

✅ Recent Catalysts (Already Happened)

Soleno Announcement — April 6, 2026: Neurocrine announced the $53/share, $2.9B acquisition of Soleno — a 34% premium. This diversifies Neurocrine beyond neuroscience into metabolic/endocrinology rare diseases. VYKAT XR's $190M first-year revenue with a $92M Q4 2025 alone shows strong commercial traction.

Q4 2025 / Full-Year 2025 Results (February 2026):

• Full-year 2025 net product sales: $2.83B, up 22% YoY
• INGREZZA: $2.51B (double-digit volume growth)
• Cash/securities: ~$2.54B at year-end — strong balance sheet entering the Soleno acquisition
• Needham remains bullish on 2026 growth expectations for both CRENESSITY and INGREZZA

Analyst Consensus: 23 of 34 analysts rate Buy, 0 Sell, average PT of $175-$183 per TipRanks — strong conviction on the street that the stock is undervalued here.

---

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, analyst targets, and catalyst timeline together:

🚀 Bull Case — $170-$215 by December 2027 (LEAP TARGET ZONE): Osavampator Phase 3 succeeds in 2027 (massive MDD indication), Soleno integration goes smoothly, INGREZZA expanded sales force drives revenue above $3B, and CRENESSITY continues ramping. The LEAP buyer is well in-the-money, potentially generating 3-5x on the $14.20 premium paid. H.C. Wainwright's $215 target would put this LEAP deep in profit. Probability over 20 months: 40%

⚖️ Base Case — $140-$165 by December 2027: INGREZZA grows steadily at 8-10% annually, Soleno adds $300-400M in VYKAT XR revenue, but no major pipeline catalyst materializes before osavampator data. Stock drifts toward analyst consensus targets but doesn't break out dramatically. The LEAP expires out-of-the-money or just barely in-the-money — breakeven requires $184.20. Probability: 35%

😰 Bear Case — Below $130 (LEAP expires worthless): INGREZZA pricing erosion accelerates, the Soleno integration disappoints on cost or VYKAT XR trajectory, and osavampator Phase 3 data is delayed or negative. Without a pipeline catalyst, the stock re-rates lower as a maturing franchise. The $2.8M premium is entirely lost. Probability: 25% — meaningful, but the 20-month time horizon reduces this risk compared to short-dated options

---

💡 Trading Ideas

🛡️ Conservative — "Ride the Analyst Consensus"

Buy NBIX stock outright and target $175 (analyst average PT)

If you believe the Soleno acquisition is correctly valued and INGREZZA keeps growing, buying the stock here at $131 with a 12-month target of $175 means a 33% return — in line with what 23 out of 34 analysts expect. No options risk, participate in any upside, manageable downside given strong fundamentals.

• 💡 Why this works: Strong earnings growth, multiple analyst Buy ratings, three-product portfolio reducing single-product risk
• ⚠️ Risk: No major pipeline catalyst until 2027; stock could tread water for months
• 🎯 Stop: Consider $115-$120 as a risk-management level (major gamma support)

⚖️ Balanced — "Mini-LEAP Like the Whale"

Buy the June 2027 $150 call (1-5 contracts)

A slightly closer-to-the-money version of this LEAP play — the $150 strike is 14% OTM instead of 29% OTM, giving you better leverage if NBIX approaches analyst targets within the next 14 months. You participate in the catalyst story (May 5 earnings, Soleno close, sales force expansion) with defined risk.

• 💡 Why this works: Gets you exposed to near-term catalysts with 14 months of runway; closer to the money means faster payoff on a breakout
• ⚠️ Risk: Full premium loss if NBIX stays flat or falls — don't size this as more than 1-3% of portfolio
• 🎯 Breakeven: ~$165-$167 at June 2027 expiration (strike + estimated premium)

🚀 Aggressive — "Earnings Momentum Play"

Buy a May 2026 $135/$145 call spread before the May 5 earnings report

The Q1 earnings on May 5 are 20 days away. If INGREZZA Q1 revenue comes in above expectations and CRENESSITY shows accelerating scripts, NBIX could gap up through the $135 gamma resistance and target $145. A call spread limits your downside while targeting the most likely near-term bull case.

• 💡 Why this works: Defined-risk earnings play; $135/$145 range captures both the first and second gamma resistance levels
• ⚠️ Risk: 100% premium loss if NBIX misses or sells off on earnings — this is a binary event
• 🎯 Max profit: ~$10/share ($1,000 per spread) if NBIX closes above $145 at May expiration

---

⚠️ Risk Factors

Let's be honest about what could derail this LEAP:

• ❗ 29% OTM with 20 months is a high bar: The stock needs to rally roughly $52 from current levels just to get in-the-money. The premium ($14.20) is 100% at risk if NBIX can't reach $170 by December 2027
• ❗ Catalyst gap in 2026: As Seeking Alpha noted, 2026 is largely a commercial execution year. No major Phase 3 data readouts until 2027 — the stock could trade sideways for 12+ months
• ❗ INGREZZA pricing headwinds: Formulary access investments are creating net price erosion that partially offsets strong volume growth. If this worsens, the flagship franchise disappoints
• ❗ Soleno integration risk: $2.9B acquisition depletes the $2.54B cash balance. If VYKAT XR growth disappoints or integration costs surge, the deal looks expensive and the stock gets punished
• ❗ Osavampator Phase 3 uncertainty: MDD has a historically high clinical failure rate. A negative 2027 data readout would be a major blow to the bull thesis — and it comes right as this LEAP approaches expiration
• ❗ IRA drug pricing risk: Potential INGREZZA inclusion on IRA negotiation list would pressure the core revenue stream longer-term

---

🎯 The Bottom Line

Real talk: This NBIX LEAP is a carefully constructed long-term thesis, not a short-term trade. The whale paying $2.8M for December 2027 $170 calls with ZERO prior open interest is telling you they've done the work. The thesis: Neurocrine at $131 is undervalued given three profitable products, strong analyst support, and a potential Phase 3 home run in osavampator by 2027.

If you're bullish long-term: The stock itself at $131 — well below the $175-$183 analyst consensus and near the 52-week midpoint — offers a compelling entry for a 12-18 month hold. You don't need the leverage of a LEAP to capture the thesis.

If you want the leveraged version: A $150 call in the June 2027 timeframe (closer to the money, comparable time horizon) gives you better risk/reward than trying to replicate the $170 LEAP strike exactly. The whale can afford to absorb the 29% OTM distance. Retail traders should lean closer.

If you're waiting: Mark May 5, 2026 for Q1 earnings — that's your first major signal on whether the INGREZZA + Soleno integration story is tracking as promised. A strong print could be the catalyst that gets NBIX moving toward those $175+ analyst targets.

---

⚠️ Disclaimer: Options trading involves substantial risk and is not suitable for all investors. LEAP options in particular can expire worthless if the underlying stock does not move sufficiently in the expected direction within the time frame. This analysis is for educational and informational purposes only and does not constitute financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.